Nippon Shinyaku Co Ltd 2017 Annual Report with Sustainability Disclosures
The report presents Nippon Shinyaku's FY2016 integrated performance, including consolidated net sales of ¥98,781 million and growth led by pharmaceuticals. It highlights development and commercialization support for rare-disease treatments such as NS-065/NCNP-01 and NS-018. Environmental results include a 13.7% reduction in total energy consumption versus fiscal 1990, while employee initiatives covered work-life balance, diversity, training, and safety.
Company: Nippon Shinyaku Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2017
Type: Annual Report with Sustainability Disclosures
Pages: 29
Back to company
Nippon Shinyaku Co Ltd
Annual Report
The report presents Nippon Shinyaku's FY2016 integrated performance, including consolidated net sales of ¥98,781 million and growth led by pharmaceuticals. It highlights development and commercialization support for rare-disease treatments such as NS-065/NCNP-01 and NS-018. Environmental results include a 13.7% reduction in total energy consumption versus fiscal 1990, while employee initiatives covered work-life balance, diversity, training, and safety.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Women on Board
Employees